MEI Pharma. has been granted a patent for novel compounds, specifically (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, which are proposed for use in treating proliferative diseases. The patent includes details on their pharmaceutical compositions and preparation methods. GlobalData’s report on MEI Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MEI Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. MEI Pharma's grant share as of July 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12059422B2 outlines a novel compound, or its pharmaceutically acceptable salt, that is designed to selectively inhibit the activity of PI3Kd, a key enzyme implicated in various disorders and cancers. The claims detail methods for utilizing this compound to treat or alleviate symptoms associated with PI3Kd-mediated conditions. Specifically, the patent describes the administration of a therapeutically effective amount of the compound to subjects suffering from these disorders, including specific applications for treating PI3Kd-mediated cancers, particularly hematological cancers such as non-Hodgkin's lymphoma.
Additionally, the patent encompasses the formulation of a pharmaceutical composition that includes the compound alongside a pharmaceutically acceptable excipient. This composition is intended for oral administration, with claims specifying that it can be formulated as a tablet or capsule. The focus on oral dosage forms suggests a consideration for patient compliance and ease of use in therapeutic settings. Overall, the patent presents a targeted approach to addressing PI3Kd-related diseases, with potential implications for the treatment of specific cancer types.
To know more about GlobalData’s detailed insights on MEI Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
